These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9271818)
1. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. Serra A; Esteve J; Reverter JC; Lozano M; Escolar G; Ordinas A Thromb Res; 1997 Aug; 87(4):405-10. PubMed ID: 9271818 [TBL] [Abstract][Full Text] [Related]
2. Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions. González-Correa JA; Arrebola MM; Mérida F; Navas MD; López-Villodres JA; Samanes F; Cruz JP J Pharmacol Sci; 2008 May; 107(1):103-6. PubMed ID: 18490857 [TBL] [Abstract][Full Text] [Related]
3. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164 [TBL] [Abstract][Full Text] [Related]
4. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305 [TBL] [Abstract][Full Text] [Related]
5. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Maugeri N; de Gaetano G; Barbanti M; Donati MB; Cerletti C Haematologica; 2005 Jun; 90(6):833-9. PubMed ID: 15951297 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy. Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530 [TBL] [Abstract][Full Text] [Related]
7. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326 [TBL] [Abstract][Full Text] [Related]
8. [The effect of unfractionated heparin and low molecular weight heparins on chemotaxis of peripheral blood neutrophils]. Krasnowska M; Zak-Nejmark T; Krasnowski R Pol Arch Med Wewn; 2001 Mar; 105(3):211-5. PubMed ID: 11680265 [TBL] [Abstract][Full Text] [Related]
9. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury. Roqué M; Rauch U; Reis ED; Chesebro JH; Fuster V; Badimon JJ Thromb Res; 2000 Jun; 98(6):499-505. PubMed ID: 10899349 [TBL] [Abstract][Full Text] [Related]
10. Suitability of low-molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model. Lozano M; Bos A; de Groot PG; van Willigen G; Meuleman DG; Ordinas A; Sixma JJ Arterioscler Thromb; 1994 Jul; 14(7):1215-22. PubMed ID: 8018678 [TBL] [Abstract][Full Text] [Related]
11. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Collen A; Smorenburg SM; Peters E; Lupu F; Koolwijk P; Van Noorden C; van Hinsbergh VW Cancer Res; 2000 Nov; 60(21):6196-200. PubMed ID: 11085545 [TBL] [Abstract][Full Text] [Related]
12. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins. Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512 [TBL] [Abstract][Full Text] [Related]
13. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature. Liu JT; Paul W; Emerson M; Cicala C; Page CP Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481 [TBL] [Abstract][Full Text] [Related]
14. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Klein B; Faridi A; von Tempelhoff GF; Heilmann L; Mittermayer C; Rath W Thromb Res; 2002 Dec; 108(5-6):291-6. PubMed ID: 12676188 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822 [TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Cziraky MJ; Spinler SA Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606 [TBL] [Abstract][Full Text] [Related]